# Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

3

1

2

- 4 Bo Shen<sup>1#</sup>, Xiao Yi<sup>2,3#</sup>, Yaoting Sun<sup>2,3#</sup>, Xiaojie Bi<sup>1#</sup>, Juping Du<sup>1#</sup>, Chao Zhang<sup>4#</sup>,
- 5 Sheng Quan<sup>4#</sup>, Fangfei Zhang<sup>2,3</sup>, Rui Sun<sup>2,3</sup>, Liujia Qian<sup>2,3</sup>, Weigang Ge<sup>2,3</sup>, Wei Liu<sup>2,3</sup>,
- 6 Shuang Liang<sup>2,3</sup>, Hao Chen<sup>2,3</sup>, Ying Zhang<sup>1</sup>, Jun Li<sup>1</sup>, Jiaqin Xu<sup>1</sup>, Zebao He<sup>1</sup>, Baofu
- 7 Chen<sup>1</sup>, Jing Wang<sup>1</sup>, Haixi Yan<sup>1</sup>, Yufen Zheng<sup>1</sup>, Donglian Wang<sup>1</sup>, Jiansheng Zhu<sup>1</sup>,
- 8 Ziqing Kong<sup>4</sup>, Zhouyang Kang<sup>4</sup>, Xiao Liang<sup>2,3</sup>, Xuan Ding<sup>2,3</sup>, Guan Ruan<sup>2,3</sup>, Nan
- 9 Xiang<sup>2,3</sup>, Xue Cai<sup>2,3</sup>, Huanhuan Gao<sup>2,3</sup>, Lu Li<sup>2,3</sup>, Sainan Li<sup>2,3</sup>, Qi Xiao<sup>2,3</sup>, Tian Lu<sup>2,3</sup>, Yi
- 10 Zhu<sup>2,3\*</sup>, Huafen Liu <sup>4\*</sup>, Haixiao Chen<sup>1\*</sup>, Tiannan Guo<sup>2,3,5\*</sup>
- <sup>1</sup>Taizhou Hospital, Wenzhou Medical University, 150 Ximen Street, Linhai 317000, Zhejiang
- 12 Province, China;
- <sup>2</sup>Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake
- 14 University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China;
- 15 <sup>3</sup>Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan
- Road, Hangzhou 310024, Zhejiang Province, China;
- <sup>4</sup>Calibra Lab at DIAN Diagnostics, 329 Jinpeng Street, Hangzhou 310030, Zhejiang Province,
- 18 China;
- 19 <sup>5</sup>Lead Contact
- 20 # co-first;
- 21 \* Correspondence: zhuyi@westlake.edu.cn (Y.Z.); liuhf1@dazd.cn (H.L.); chenhx@enzemed.com
- 22 (H.C.); guotiannan@westlake.edu.cn (T.G.)

23

24

# **SUMMARY**

- 25 Severe COVID-19 patients account for most of the mortality of this disease.
- 26 Early detection and effective treatment of severe patients remain major
- challenges. Here, we performed proteomic and metabolomic profiling of sera
- from 46 COVID-19 and 53 control individuals. We then trained a machine
- 29 learning model using proteomic and metabolomic measurements from a
- training cohort of 18 non-severe and 13 severe patients. The model correctly
- classified severe patients with an accuracy of 93.5%, and was further
- validated using ten independent patients, seven of which were correctly
- classified. We identified molecular changes in the sera of COVID-19 patients
- implicating dysregulation of macrophage, platelet degranulation and
- complement system pathways, and massive metabolic suppression. This
- 36 study shows that it is possible to predict progression to severe COVID-19
- disease using serum protein and metabolite biomarkers. Our data also
- 38 uncovered molecular pathophysiology of COVID-19 with potential for
- 39 developing anti-viral therapies.

40

# INTRODUCTION

41

42

43

44

45

46

47

48

49

50

51

52

53

54 55

56

57

58

59

60

61 62

63

64

65

66

67 68

69

70

71

72

73

74

75

Coronavirus disease 2019 (COVID-19) is an unprecedented global threat caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is currently spreading around the world rapidly. The sudden outbreak and accelerated spreading of SARS-CoV-2 infection have caused substantial public concerns. Within about two months, close to one million individuals worldwide have been infected, leading to about 50,000 deaths. At the time of writing this manuscript, about 100,000 new infections are reported daily.

Most COVID-19 studies have focused on its epidemiological and clinical characteristics(Ghinai et al., 2020; Guan et al., 2020; Li et al., 2020b; Team, 2020). About 80% of patients infected with SARS-CoV-2 displayed mild symptoms with good prognosis(Team, 2020). They usually recover with, or even without, conventional medical treatment, and therefore are classified as mild or moderate COVID-19 (Medicine, 2020; Thevarajan et al., 2020). However, about 20% of patients suffer from respiratory distress and require immediate oxygen therapy or other inpatient interventions, including mechanical ventilation (Medicine, 2020; Murthy et al., 2020; Wu and McGoogan, 2020). These patients, classified as clinically severe or critical lifethreatening infections, are mainly diagnosed empirically based on a set of clinical characteristics, such as respiratory rate (≥ 30 times/min), mean oxygen saturation (≤ 93% in the resting state) or arterial blood oxygen partial pressure/oxygen concentration (≤ 300 mmHg) (Medicine, 2020). However, patients exhibiting these clinical manifestations have already progressed to a clinically severe phase and require immediate access to specialized intensive care; otherwise, they may die rapidly. Therefore, it is critical to develop new approaches to predict early which cases will likely become clinically severe. In addition, effective therapy for severe patients remains speculative, largely due to limited understanding of SARS-CoV-2 pathogenesis.

In this study, we hypothesized that SARS-CoV-2 induces characteristic molecular changes that can be detected in the sera of severe patients. These molecular changes may shed light on therapy development for COVID-19 patients. To test this hypothesis, we applied cutting-edge proteomic (Aebersold and Mann, 2016; Li et al., 2020a) and metabolomic (Hou et al., 2020; Lee et al., 2019) technologies to analyze the proteome and metabolome of sera from severe COVID-19 patients and several control groups.

76 77

78

79

80

81

82

# **RESULTS**

# Proteomic and metabolomic profiling of COVID-19 sera

We procured a cohort of patients (Zheng et al., 2020) containing 21 severe COVID-19 patients, in which 11 sera from severe patients were collected one to six days before the patients were clinically assessed as

severe. Sera from the remaining eight patients were collected within about 3 days after diagnosed as severe cases (Figure 1A, Table 1, Table S1). Controls with matched epidemiological features were included to identify severity-related molecular alterations. These controls were 28 healthy subjects, 25 non-COVID-19 patients (negative for the SARS-CoV-2 nucleic acid test) with similar clinical characteristics as COVID-19 patients, and 25 non-severe COVID-19 patients. A serum sample was obtained from each patient within a few days after hospital admission, with a few exceptions when samplings were performed at later disease stages.

We used stable isotope labeled proteomics strategy TMTpro (16plex) (Li et al., 2020a) and UPLC-MS/MS untargeted metabolomics approach to analyze 92 undepleted sera from 86 individuals. Altogether 894 proteins were quantified and 941 (including 36 drugs and their metabolites) metabolites were identified with authentic compound library searching. For metabolomic analysis, both hydrophilic and hydrophobic molecules were analyzed using both positive and negative ionization to cover various endogenous biochemical classes. Our data were acquired with high degree of consistency and reproducibility. In quality control analysis, the median coefficient of variance (CV) values for proteomic and metabolomic data were 10% and 5%, respectively (Figure S1A). Remarkably, sera from SARS-CoV-2 infected patients were well resolved from healthy individuals, and the sera from severe patients displayed distinct proteomic and metabolomic patterns compared to those from other groups (Figures S1B-C).

## Identification of severe patients using machine learning

We next investigated the possibility of classify the severe COVID-19 patients based on the molecular signatures of proteins and metabolites (Table S2). We built a random forest machine learning model based on proteomic and metabolomic data from 18 non-severe and 13 severe patients (Figure 1B), leading to prioritization of 29 important variables including 22 proteins and 7 metabolites (Figure 2A-B). This model reached an AUC of 0.957 in the training set (Figure 2C). One non-severe patient, XG3, was incorrectly classified as severe (Figure 2D), possibly because this 70-year-old male patient was the oldest individual in this cohort (Figure 1A). For patient XG40, the reason of incorrectly classified is unclear.

We then tested the model on an independent cohort of ten patients (Figure 2E, Table S3). All severe patients were correctly identified, except one patient, XG45, a 62-year-old male who had received traditional Chinese medicines during more than 20 days before admission. This individual was the patient with the longest pre-admission treatment in this cohort and the administration of traditional Chinese medicines might have also accounted for the incorrect prediction. Another incorrectly classified non-severe patient was XG22, a 43 year-old male with chronic HBV infection and diabetes who had the longest hospitalization (>50 days) among all non-severe patients. Indeed,

our molecular-based prediction flagged him as an outlier, suggesting that his prolonged treatment history might have interfered with the expression of the panel of the 29 variables. For reasons yet unclear, XG25, a 43-year-old male non-severe case, was incorrectly classified as severe.

## Proteomic and metabolomic changes in severe COVID-19 sera

We found that 105 proteins were differentially expressed in COVID-19 patients, but not in the non-COVID-19 patients (Figure S2, S4). After correlating their expression with clinical disease severity (Figure S5), 93 proteins showed specific modulation in severe patients. Pathway analysis and network enrichment analyses of the 93 differentially expressed proteins revealed three pathways (Figure S6), namely activation of the complement system, macrophage function and platelet degranulation, involving 50 proteins (Figure 3A) in the sera of severe patients. Similarity, 373 and 204 metabolites were found with differential abundance in COVID-19 patients and continually changed correlated with disease severity in our metabolomics data, respectively (Figure S3, S4). Correspondingly, 82 metabolites were involved in the three biological processes. We summarize the key dysregulated molecules in Figure 5 and discussed in the following sections.

# Dysregulated macrophage and lipid metabolism

Our data uncovered dysregulation of multiple apolipoproteins including APOA1, APOA2, APOH, APOL1, APOD and APOM (Figure 3A). Most of them are associated with macrophage function and were down-regulated. Decrease of APOA1 in serum has been reported during the transition of COVID-19 patients from mild to severe illness (Nie et al., 2020). The APOM in serum of severe patients was downregulated compared with healthy and non-severe COVID-19 patients. Regulation of serum APOM has also been observed in hepatitis B virus (HBV) patients (Gu et al., 2011).

Consistent with these proteomic findings, we also detected dysregulated metabolites involved in lipid metabolism. Accumulation of 16 steroid hormones in COVID-19 patients may contribute to macrophage modulation. Steroid hormones, including progesterone, androgens, estrogens and bile acids can promote the activity of macrophages (Vernon-Roberts, 1969). Specifically, glucocorticoids were recently reported to be clinically efficacious (Wang et al., 2020b). We detected increased 21-hydroxypregnenolone, the essential intermediate for synthesizing corticosterone, suggesting that corticosterone biosynthesis may be a protective mechanism against SARS-CoV-2 infection.

We also found evidence of significant activation of the kynurenine pathway. Metabolites of kynurenate, kynurenine, 8-methoxykynurenate were enriched in COVID-19 patients. Nicotinamide adenine dinucleotide (NAD+), the cofactor in many cellular redox reactions, can be synthesized from tryptophan by the kynurenine pathway and operates as a switch for macrophage effector responses (Minhas et al., 2019).

The macrophage process is closely related to lipid metabolism. Over 100 lipids were down-regualted in severe patients. Our data showed decreased sphingolipids in both non-severe and severe COVID-19 patients (Figure 4A). Sphingolipids and glycerophospholipids are important components of biomembranes, which mediate signal transduction and immune activation processes. Sphingolipids, such as sphingosine-1-phosphate, can induce macrophage activation, inhibit macrophage apoptosis, and promote migration of macrophages to inflammatory sites (Weigert et al., 2009). Phagocytosis and platelet degranulation are coupled with changes in biomembrane lipid composition and fluidity, and modulate the production of glycerophospholipids (Rouzer et al., 2007). In this study, we found continuous decrease of glycerophospholipids after SARS-CoV-2 infection. Glycerophospholipids and fatty acids such as arachidonic acid have been found significantly elevated in HCoV-229E-infected cells, and exogenous supplement of arachidonic acid significantly suppressed HCoV-229E and MERS-CoV replication (Yan et al., 2019). Our data suggest severe COVID-19 patients might benefit from this therapeutical strategy as well.

Choline and its derivatives were down-regulated in COVID-19 patients, particularly in severe cases; phosphocholine, the intermediate product for producing phosphatidylcholine (PC) was up-regulated (Figure 4B). This was probably due to activated macrophage-mediated immunity (Sanchez-Lopez et al., 2019). Polarization of macrophages in response to pathogens requires increased absorption of choline for PC formation, thereby promoting cytokine secretion (Sanchez-Lopez et al., 2019).

194195196

197

198 199

200

201

202

203

204

205

206

207

208

209

210

211212

213

214

171

172

173174

175

176

177

178

179

180

181

182

183

184

185 186

187

188

189

190

191

192193

#### Activated acute phase proteins (APPs) and the complement system

We detected 10 APPs among 20 proteins that are differentially expressed between non-severe and severe groups (Figure 2A). They are involved at the early stages of immune responses to virus infection. Among the most significantly upregulated in severe sera were APPs, including serum amyloid A-1 (SAA1), serum amyloid A-2 (SAA2), serum amyloid A-4 (SAA4), Creactive protein (CRP), alpha-1-antichymotrypsin (SERPINA3) and serum amyloid P-component (SAP/APCS) (Figure 3B). Some of them are known to be biomarkers for viral infections, including SAA1, SAA2 and CRP. While CRP has been associated with COVID-19, the other proteins have not previously been reported in COVID-19 (Liang et al., 2020). SAA1 was reported to be elevated in severe SARS patients, but was not specific to SARC-CoV (Pang et al., 2006). As a major contributor to acute phase response, complement system plays a crucial role in eliminating invading pathogens in the early stage of infection. Among those APPs, two proteins belong to the complement membrane attack complex, including complement 6 (C6) and complement factor B (CFB). Two other proteins, Properdin (CFP) and Carboxypeptidase N catalytic chain (CPN1), are regulators of complement system (Figure 3).

We also observed an accumulation of mannose and its derivatives in severe patients. In the complement system, binding of mannose to lectin leads to cleaveage of C2 and C4, which then form a C3 convertase to promote complement activation (Ricklin et al., 2010).

#### Suppressed platelet degranulation in severe sera

Fifteen of 17 proteins involved in platelet degranulation were down-regulated in SARS-CoV-2 infected patients, which may be associated with observed thrombocytopenia in this patient cohort (Zheng et al., 2020). Low platelet count is also reported to be associated with severe COVID-19 and mortality (Lippi et al., 2020). Two of the most intriguing proteins down-regulated in severe patients are platlet expressing chemokines pro-platelet basic protein (PPBP; also called macrophage-derived growth factor) and platelet factor 4 (PF4). PF-4 was identified as a broad-spectrum HIV-1 inhibitor at the level of virus attachment and entry via interaction with the major viral envelope glycoprotein gp120 (Auerbach et al., 2012). In another sera proteomic investigation of SARS, they found decreasing PF4 was associated with poor prognosis (Poon et al., 2012), in consistent with our findings regarding COVID-19.

Most enterochromaffin cell-derived serotonins (5-hydroxytryptamine [5-HT]) are transported to platelets for storage and release (Baganz and Blakely, 2013). Our previous data showed that when platelet counts in COVID-19 patients decrease as the severity of the disease increase (Zheng et al., 2020), serotonin (Figure 4B) level decreases accordingly. Compared with the healthy group, serotonin in non-severe and severe COVID-19 patients decreased by 2.07-fold (p = 1.86e-04) and 3.31-fold (p = 9.07e-07), respectively.

We also detected low levels of fatty acids such as arachidonate and docosapentaenoate in COVID-19 patients (Figure 4), which may be related to their decreased platelet counts. Fatty acids including arachidonate (20:4n6) are active factors of platelet degranulation. A study on H7N9 reported that H7N9 infection led to suppression of various fatty acids including palmitic acid (Sun et al., 2018). We also found palmitic acid decreased in severe COVID-19 patients.

## Massive suppression of amino acids in the sera of COVID-19 patients

More than 100 decreased metabolites in the sera of COVID-19 patients are amino acids and their derivatives were found significantly decreased in the sera of COVID-19 patients compared to their levels in the healthy controls, while their levels were either unchanged or even increased in the sera of non-COVID-19 patients. Enriched in these metabolites are ten metabolites involved in arginine metabolism including glutamate, arginine, N-(l-arginino)succinate, citrulline, ornithine, glutamine, 2-oxoglutarate, N-acetyl-L-glutamate, urea, and fumarate. In addition, some arginine derivatives such as argininate, asymmetric dimethylarginine, symmetric dimethylarginine,

homoarginine and N-acetylarginine, were also significantly decreased in the sera of non-severe COVID-19 patients. It has been reported that arginine metabolism is suppressed in severe fever with thrombocytopenia syndrome caused by a SFTS bunyavirus (SFTSV)(Li et al., 2018b). Decreased arginine levels in SFTSV patients was associated with impaired anti-SFTSV functions of T cells.

# **DISCUSSION**

# **Prediction of severe COVID-19 patients**

Although COVID-19 can be diagnosed effectively by nucleic acid-based methods at an early stage, it is equally critical to identify severe COVID-19 patients before their manifestion of severe symptoms to minimize mortality. In this study we show that severe cases can be predicted by molecular signatures of metabolites and proteins using a machine learning model based on the expression levels of 22 serum proteins and seven metabolites (Figure 2A-B). We achieved an overall accuracy of 93.5% in the training set. Prediction of two patients did not match clinical diagnosis. One of them is nonsevere individual who was the oldest patient in the training cohort. Remarkably, nine severe patients were correctly identified retrospectively based on the analysis of their sera collected one to six days before they were clinically diagnosed as having deteriorated to a severe state (Figure 1, Figure 2D), suggesting that their sera protein and metabolite signatures at the sampling time were already pointing to further deterioration into severe state even when severe clinical symptoms have not started to appear yet.

The proteins and metabolites used in our classifier (Figure 2A) contain several known biomarkers for viral infections, such as SAA2, SSA1 and CRP, which have already been used empirically to monitor the severity of COVID-19. Our study suggests that more characteristic molecular changes at protein and metabolite levels can be used to build a predictive model for the prospective identification of severe cases. The classifier also included exceptionally high levels of other acute phase proteins, including SERPINA3, among others (Figure 2A-B). Our data suggest potential benefits of broader testing of these proteins in newly diagnosed cases to identify which COVID-19 patients are likely to progress to severe disease. The model contains molecules involved in hepatic damage. The elevation of glucose, glucuronate. bilirubin degradation product and four bile acid derivatives, suggests suppressed hepatic detoxification (Rowland et al., 2013). Vascular cell adhesion protein 1 (VCAM-1) which helps to regulate transendothelial migration of leukocytes by stimulating production of reactive oxygen species (ROS), was upregulated in our data. As apotent antioxidant and inhibitor of VCAM-1 dependent cellular events (Keshavan et al., 2005), bilirubin was found to be down-regulated in our metabolomic data.

Seven patients were correctly classified in the independent validation cohort containing ten patients. Two of them could be explained by the patients' complex comorbidity and medication history. The relatively small sample size necessitates future validation studies in independent cohorts.

304 305 306

307

308

309

310

311

312

313

314

315316

317

318

319

320

321

322323

324

325

326

327

328 329

330

331

332

301 302

303

#### Molecular insights for pathogenesis of SARS-CoV-2 infection

Our data shed light on the molecular changes reflected in COVID-19 sera which could potentially yield critical diagnostic markers or therapeutic targets for managing severe COVID-19 patients (Figure 5). These molecular derangements may originate from binding of SARS-CoV-2 to alveolar macrophages via the ACE2 receptor (Hoffmann et al., 2020), resulting in release of IL-6 and TNF-α (Mehta et al., 2020) by macrophages (Gabay and Kushner, 1999). In response to elevated cytokines, especially IL-6 which triggers fever, the liver releases various APPs. Activation of APPs is accompanied with the immunogenesis or organic damage (Gabay and Kushner, 1999). Our metabolomics data also provide plausible evidence for hepatic injury. In physiological condition, hormone or bilirubin binds to glucuronate, a derivative of glucose, for liver detoxification (Rowland et al., 2013). The elevation of glucose, glucuronate, bilirubin degradation product and four bile acid derivatives in severe patients, indicating the potential declined detoxification function (Figures 4-5). Indeed, our data showed an upregulation of multiple APPs, including CRP and major attack complexes (MACs) in the severe sera. CRP can activate the complement system (Chirco and Potempa, 2018). This on the one hand leads to enhanced cytokine and chemokine production, potentially contributing to "cytokine storm"; and on the other overly recruits macrophages from the peripheral blood, which could result in acute lung injury(Chirco and Potempa, 2018; Narasaraju et al., 2011). Because about 50% of platelets are produced in the lung (Lefrancais et al., 2017), platelet may in turn respond to lung injury and activate macrophases by degranulation (Mantovani and Garlanda, 2013), which may further add to "cytokine storm". A recent necropsy report revealed alveolar macrophage infiltration and activation in severe COVID-19 patients (Liao M., 2020), supporting our findings.

333334335

336

337

338

339

340

341342

343

## **Insights for COVID-19 therapeutics**

To date, few other therapies are proven effective for severe COVID-19 patients. Most of patients receive standard supportive care and antiviral therapy (Wang et al., 2020a). Corticosteroid treatment which are effectively in suppressing MERS-CoV and SARS-CoV (Arabi et al., 2018), but showed negligible effect on COVID-19 patients and may even have induced lung injury (Russell et al., 2020). The molecular changes revealed in this study in the COVID-19 sera have allowed us to propose potential new therapeutic strategies for the severe patients.

Our proteomic data showed that proteins related to platelet degranulation were substantially down-regulated in severe patients, a finding which was confirmed by low platelet counts (Zheng et al., 2020). The association between thrombocytopenia and viral infection has been observed in SARS-CoV (Zou et al., 2004), hepatitis C virus (HCV) (Assinger, 2014), and Dengue virus (Wilder-Smith et al., 2004). We thus recommend watching closely monitoring changes in platelets and making interventions, such as infusions of thrombopoietin (TPO) as necessary, particularly when liver or kidney injuries occur.

Complement activation suppresses virus invasion, and may lead to inflammatory syndromes (Barnum, 2016). Our data showed a general upregulation of complement system proteins, including MAC proteins such as C5, C6 and C8. Suppression of complement system has been reported as an effective immunotherapeutics in SARS-infected mouse model (Gralinski et al., 2018). C5a has been reported as highly expressed in severe SARS and MERS patients as well (Wang et al., 2015). Inhibition of C5a has been reported to alleviate viral infection-induced acute lung injury (Garcia et al., 2013; Jiang et al., 2018; Sun et al., 2014). Our data suggest that severe COVID-19 patients might benefit from suppression of complement system.

The coronavirus are enveloped, positive strand RNA viruses, the replication and assembly of which consume large amount of lipids. Our metabolomics results showed that more than 100 lipids including glycerophospholipid, sphingolipids and fatty acids were down-regulated in COVID-19 patients sera, probably due to rapid replication of the virus. Glycerophospholipid, sphingolipids (one of the components of lipid rafts) and fatty acids have been reported to play an important role in the early development of enveloped viruses (Schoggins and Randall, 2013). Suppression of cholesterol synthesis by M $\beta$ CD has been reported inhibiting the production of SARS-CoV particles released from infected Vero E6 cells (Li et al., 2007). Drugs inhibiting lipid synthesis such as statin have been proposed to treat HCV (Heaton and Randall, 2011) and COVID-19 (Fedson et al., 2020). Our data also supports this potential therapeutics for severe COVID-19 patients.

SARS-CoV-2 is highly infectious, applying huge pressure to the medical system worldwide. Upon COVID-19 outbreak, limited information of this pathogen was available, which restricted the collection of clinical specimens for this study. The reason for the small sample size of this study were biosafety constraints.

In conclusion, this study presents a systematic proteomic and metabolimic investigation of sera from multiple COVID-19 patient groups and control groups. We show that feasibility of predicting severe COVID-19 patients based on a panel of serum proteins and metabolites. Our data offer a landscape of blood molecular changes induced by SARS-CoV-2 infection, which may provide useful diagnositic markers and therapeutic targets.

388

390

400

408

412

417

389

# **ACKNOWLEDGEMENTS**

- 391 This work is supported by grants from Westlake Special Program for COVID-
- 392 19 (2020), and Tencent foundation (2020), National Natural Science
- 393 Foundation of China (81972492, 21904107, 81672086), Zhejiang Provincial
- 394 Natural Science Foundation for Distinguished Young Scholars
- (LR19C050001), Hangzhou Agriculture and Society Advancement Program
- 396 (20190101A04). We thank Drs. R. Aeberold, O.L. Kon, H. Yu, D. Li, and the
- Guomics team for invaluable comments to this study. We thank Westlake
- 398 University Supercomputer Center for assistance in data storage and
- 399 computation.

# **AUTHOR CONTRIBUTIONS**

- T.G., H.C., H.L., B.S. and Y.Z. designed and supervised the project. B.S.,
- 402 X.B., J.D., Y.Z., J.L., J.X., Z.H., B.C., J.W., H.Y., Y.Z., D.W. and J.Z. collected
- 403 the samples and clinical data. X.Y., Y.S., F.Z., R.S., L.Q., W.G., W.L., S.L.,
- 404 H.C., X.L., X.D., G.R., N.X., X.C., H.G., L.L., S.L., Q.X. and T.L. conducted
- proteomic analysis. Data were interpreted and presented by all co-authors.
- 406 C.Z., S.Q., Z.K. and Z.K. conducted metabolomic analysis. T.G. wrote the
- 407 manuscript with inputs from co-authors.

# **DECLARATION OF INTERESTS**

- The research group of T.G. is partly supported by Tencent, Thermo Fisher
- Scientific, SCIEX and Pressure Biosciences Inc. C.Z., Z.K., Z.K. and S.Q. are
- 411 employees of DIAN Diagnostics.

## DATA AVAILABILITY

- All data are available in the manuscript or the supplementary material. The
- 414 proteomics and metabolomics data are deposited in ProteomeXchange
- 415 Consortium (https://www.iprox.org/). Project ID: IPX0002106000. All the data
- will be publicly released upon publication.

# REFERENCES

- 418 Aebersold, R., and Mann, M. (2016). Mass-spectrometric exploration of proteome structure and
- 419 function. Nature *537*, 347-355.
- 420 Arabi, Y.M., Mandourah, Y., Al-Hameed, F., Sindi, A.A., Almekhlafi, G.A., Hussein, M.A., Jose, J.,
- 421 Pinto, R., Al-Omari, A., Kharaba, A., et al. (2018). Corticosteroid Therapy for Critically III Patients
- with Middle East Respiratory Syndrome. Am J Respir Crit Care Med 197, 757-767.
- 423 Assinger, A. (2014). Platelets and infection an emerging role of platelets in viral infection. Front
- 424 Immunol *5*, 649.
- 425 Auerbach, D.J., Lin, Y., Miao, H., Cimbro, R., Difiore, M.J., Gianolini, M.E., Furci, L., Biswas, P., Fauci,
- 426 A.S., and Lusso, P. (2012). Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-

- 427 spectrum HIV-1 inhibitor. Proc Natl Acad Sci U S A 109, 9569-9574.
- 428 Baganz, N.L., and Blakely, R.D. (2013). A dialogue between the immune system and brain, spoken
- in the language of serotonin. ACS Chem Neurosci 4, 48-63.
- 430 Barnum, S. (2016). Complement: A Primer for the Coming Therapeutic Revolution. Pharmacology
- 431 & Therapeutics *172*.
- Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.H., Pages,
- 433 F., Trajanoski, Z., and Galon, J. (2009). ClueGO: a Cytoscape plug-in to decipher functionally
- grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091-1093.
- 435 Chirco, K.R., and Potempa, L.A. (2018). C-Reactive Protein As a Mediator of Complement Activation
- and Inflammatory Signaling in Age-Related Macular Degeneration. Frontiers in Immunology 9,
- 437 539.
- 438 Fedson, D.S., Opal, S.M., and Rordam, O.M. (2020). Hiding in Plain Sight: an Approach to Treating
- 439 Patients with Severe COVID-19 Infection. mBio 11.
- 440 Gabay, C., and Kushner, I. (1999). Acute-Phase Proteins and Other Systemic Responses to
- Inflammation. New England Journal of Medicine *340*, 448-454.
- 442 Gao, H., Zhang, F., Liang, S., Zhang, Q., Lyu, M., Qian, L., Liu, W., Ge, W., Chen, C., Yi, X., et al. (2020).
- 443 Accelerated Lysis and Proteolytic Digestion of Biopsy-Level Fresh-Frozen and FFPE Tissue Samples
- 444 Using Pressure Cycling Technology. Journal of Proteome Research.
- 445 Garcia, C.C., Weston-Davies, W., Russo, R.C., Tavares, L.P., Rachid, M.A., Alves-Filho, J.C., Machado,
- 446 A.V., Ryffel, B., Nunn, M.A., and Teixeira, M.M. (2013). Complement C5 activation during influenza
- A infection in mice contributes to neutrophil recruitment and lung injury. PLoS One 8, e64443-
- 448 e64443.
- Ghinai, I., McPherson, T.D., Hunter, J.C., Kirking, H.L., Christiansen, D., Joshi, K., Rubin, R., Morales-
- Estrada, S., Black, S.R., Pacilli, M., et al. (2020). First known person-to-person transmission of severe
- acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. The Lancet.
- 452 Gralinski, L.E., Sheahan, T.P., Morrison, T.E., Menachery, V.D., Jensen, K., Leist, S.R., Whitmore, A.,
- Heise, M.T., and Baric, R.S. (2018). Complement Activation Contributes to Severe Acute Respiratory
- 454 Syndrome Coronavirus Pathogenesis. mBio *9*, e01753-01718.
- 455 Gu, J.-G., Zhu, C.-I., Cheng, D.-z., Xie, Y., Liu, F., and Zhou, X. (2011). Enchanced levels of
- apolipoprotein M during HBV infection feedback suppresses HBV replication. Lipids Health Dis 10,
- 457 154-154.
- 458 Guan, W.-j., Ni, Z.-y., Hu, Y., Liang, W.-h., Ou, C.-q., He, J.-x., Liu, L., Shan, H., Lei, C.-l., Hui, D.S.C.,
- 459 et al. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of
- 460 Medicine.
- Heaton, N.S., and Randall, G. (2011). Multifaceted roles for lipids in viral infection. Trends Microbiol
- 462 *19*, 368-375.
- Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T.S.,
- 464 Herrler, G., Wu, N.H., Nitsche, A., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and
- TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell.
- 466 Hou, Y.C., Yu, H.C., Martin, R., Cirulli, E.T., Schenker-Ahmed, N.M., Hicks, M., Cohen, I.V., Jonsson,
- 467 T.J., Heister, R., Napier, L., et al. (2020). Precision medicine integrating whole-genome sequencing,
- 468 comprehensive metabolomics, and advanced imaging. Proc Natl Acad Sci U S A 117, 3053-3062.
- 469 Jiang, Y., Zhao, G., Song, N., Li, P., Chen, Y., Guo, Y., Li, J., Du, L., Jiang, S., Guo, R., et al. (2018).
- Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with

- 471 MERS-CoV. Emerg Microbes Infect 7, 77-77.
- Keshavan, P., Deem, T.L., Schwemberger, S.J., Babcock, G.F., Cook-Mills, J.M., and Zucker, S.D.
- 473 (2005). Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. J
- 474 Immunol *174*, 3709-3718.
- Kramer, A., Green, J., Pollard, J., Jr., and Tugendreich, S. (2014). Causal analysis approaches in
- 476 Ingenuity Pathway Analysis. Bioinformatics *30*, 523-530.
- Lee, A.H., Shannon, C.P., Amenyogbe, N., Bennike, T.B., Diray-Arce, J., Idoko, O.T., Gill, E.E., Ben-
- 478 Othman, R., Pomat, W.S., van Haren, S.D., et al. (2019). Dynamic molecular changes during the first
- week of human life follow a robust developmental trajectory. Nat Commun 10, 1092.
- Lefrancais, E., Ortiz-Munoz, G., Caudrillier, A., Mallavia, B., Liu, F., Sayah, D.M., Thornton, E.E.,
- Headley, M.B., David, T., Coughlin, S.R., et al. (2017). The lung is a site of platelet biogenesis and a
- reservoir for haematopoietic progenitors. Nature *544*, 105-109.
- 483 Li, G.M., Li, Y.G., Yamate, M., Li, S.M., and Ikuta, K. (2007). Lipid rafts play an important role in the
- early stage of severe acute respiratory syndrome-coronavirus life cycle. Microbes Infect *9*, 96-102.
- Li, J., Van Vranken, J.G., Pontano Vaites, L., Schweppe, D.K., Huttlin, E.L., Etienne, C., Nandhikonda,
- P., Viner, R., Robitaille, A.M., Thompson, A.H., et al. (2020a). TMTpro reagents: a set of isobaric
- labeling mass tags enables simultaneous proteome-wide measurements across 16 samples. Nat
- 488 Methods
- 489 Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K.S.M., Lau, E.H.Y., Wong, J.Y.,
- 490 et al. (2020b). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected
- 491 Pneumonia. N Engl J Med.
- 492 Li, T., Kim, A., Rosenbluh, J., Horn, H., Greenfeld, L., An, D., Zimmer, A., Liberzon, A., Bistline, J.,
- 493 Natoli, T., et al. (2018a). GeNets: a unified web platform for network-based genomic analyses. Nat
- 494 Methods 15, 543-546.
- 495 Li, X.K., Lu, Q.B., Chen, W.W., Xu, W., Liu, R., Zhang, S.F., Du, J., Li, H., Yao, K., Zhai, D., et al. (2018b).
- 496 Arginine deficiency is involved in thrombocytopenia and immunosuppression in severe fever with
- 497 thrombocytopenia syndrome. Sci Transl Med 10.
- 498 Liang, T., Cai, H., Chen, Y., Chen, Z., Fang, Q., Han, W., Hu, S., Li, J., Li, T., Lu, X., et al. (2020).
- 499 Handbook of COVID-19 Prevention and Treatment
- Liao M., e.a. (2020). The landscape of lung bronchoalveolar immune cells in COVID-19 revealed
- 501 by single-cell RNA sequencing, medRxiv, https://doi.org/10.1101/2020.1102.1123.20026690.
- 502 Lippi, G., Plebani, M., and Henry, B.M. (2020). Thrombocytopenia is associated with severe
- 503 coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 506, 145-148.
- Mantovani, A., and Garlanda, C. (2013). Platelet-macrophage partnership in innate immunity and
- inflammation. Nat Immunol *14*, 768-770.
- 506 Medicine, N.H.C.o.t.P.s.R.o.C.a.N.A.o.T.C. (2020). Chinese Government Diagnosis and Treatment
- 507 Guideline (Trial 5th version).
- Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., Manson, J.J., and Hlh Across
- 509 Speciality Collaboration, U.K. (2020). COVID-19: consider cytokine storm syndromes and
- immunosuppression. Lancet *395*, 1033-1034.
- Minhas, P.S., Liu, L., Moon, P.K., Joshi, A.U., Dove, C., Mhatre, S., Contrepois, K., Wang, Q., Lee, B.A.,
- 512 Coronado, M., et al. (2019). Macrophage de novo NAD(+) synthesis specifies immune function in
- aging and inflammation. Nat Immunol 20, 50-63.
- Murthy, S., Gomersall, C.D., and Fowler, R.A. (2020). Care for Critically III Patients With COVID-19.

- 515 JAMA.
- Narasaraju, T., Yang, E., Samy, R.P., Ng, H.H., Poh, W.P., Liew, A.A., Phoon, M.C., van Rooijen, N.,
- and Chow, V.T. (2011). Excessive neutrophils and neutrophil extracellular traps contribute to acute
- 518 lung injury of influenza pneumonitis. Am J Pathol *179*, 199-210.
- Nie, S., Zhao, X., Zhao, K., Zhang, Z., Zhang, Z., and Zhang, Z. (2020). Metabolic disturbances and
- 520 inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective
- 521 study. medRxiv, 2020.2003.2024.20042283.
- Pang, R.T., Poon, T.C., Chan, K.C., Lee, N.L., Chiu, R.W., Tong, Y.K., Chim, S.S., Sung, J.J., and Lo, Y.M.
- 523 (2006). Serum amyloid A is not useful in the diagnosis of severe acute respiratory syndrome. Clin
- 524 Chem *52*, 1202-1204.
- Poon, T., Pang, R., Chan, K.C.A., Lee, N., Chiu, R., Tong, Y.-K., Chim, S., Ngai, S.M., Sung, J., and Lo,
- D. (2012). Proteomic analysis reveals platelet factor 4 and beta-thromboglobulin as prognostic
- markers in severe acute respiratory syndrome. Electrophoresis *33*, 1894-1900.
- Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J.D. (2010). Complement: a key system for
- immune surveillance and homeostasis. Nat Immunol *11*, 785-797.
- Rouzer, C.A., Ivanova, P.T., Byrne, M.O., Brown, H.A., and Marnett, L.J. (2007). Lipid profiling reveals
- 531 glycerophospholipid remodeling in zymosan-stimulated macrophages. Biochemistry 46, 6026-
- 532 6042.
- Rowland, A., Miners, J.O., and Mackenzie, P.I. (2013). The UDP-glucuronosyltransferases: Their role
- 534 in drug metabolism and detoxification. The International Journal of Biochemistry & Cell Biology
- 535 *45*, 1121-1132.
- Russell, C.D., Millar, J.E., and Baillie, J.K. (2020). Clinical evidence does not support corticosteroid
- treatment for 2019-nCoV lung injury. Lancet *395*, 473-475.
- 538 Sanchez-Lopez, E., Zhong, Z., Stubelius, A., Sweeney, S.R., Booshehri, L.M., Antonucci, L., Liu-Bryan,
- R., Lodi, A., Terkeltaub, R., Lacal, J.C., et al. (2019). Choline Uptake and Metabolism Modulate
- Macrophage IL-1beta and IL-18 Production. Cell Metab *29*, 1350-1362 e1357.
- 541 Schoggins, J.W., and Randall, G. (2013). Lipids in innate antiviral defense. Cell Host Microbe 14,
- 542 379-385.
- 543 Sun, S., Zhao, G., Liu, C., Fan, W., Zhou, X., Zeng, L., Guo, Y., Kou, Z., Yu, H., Li, J., et al. (2014).
- Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African
- Green Monkeys. Clinical Infectious Diseases *60*, 586-595.
- 546 Sun, X., Song, L., Feng, S., Li, L., Yu, H., Wang, Q., Wang, X., Hou, Z., Li, X., Li, Y., et al. (2018). Fatty
- Acid Metabolism is Associated With Disease Severity After H7N9 Infection. EBioMedicine 33, 218-
- 548 229.
- Team, T.N.C.P.E.R.E. (2020). The epidemiological characteristics of an outbreak of 2019 novel
- coronavirus diseases (COVID-19) in China. 41, 145-151.
- Thevarajan, I., Nguyen, T.H.O., Koutsakos, M., Druce, J., Caly, L., van de Sandt, C.E., Jia, X., Nicholson,
- 552 S., Catton, M., Cowie, B., et al. (2020). Breadth of concomitant immune responses prior to patient
- recovery: a case report of non-severe COVID-19. Nature Medicine.
- Vernon-Roberts, B. (1969). The effects of steroid hormones on macrophage activity. Int Rev Cytol
- 555 *25*, 131-159.
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al.
- 557 (2020a). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected
- 558 Pneumonia in Wuhan, China. JAMA.

- Wang, R., Xiao, H., Guo, R., Li, Y., and Shen, B. (2015). The role of C5a in acute lung injury induced
- by highly pathogenic viral infections. Emerg Microbes Infect 4, e28-e28.
- Wang, T., Du, Z., Zhu, F., Cao, Z., An, Y., Gao, Y., and Jiang, B. (2020b). Comorbidities and multi-
- organ injuries in the treatment of COVID-19. Lancet *395*, e52.
- Weigert, A., Weis, N., and Brune, B. (2009). Regulation of macrophage function by sphingosine-1-
- 564 phosphate. Immunobiology 214, 748-760.
- Wilder-Smith, A., Earnest, A., and Paton, N.I. (2004). Use of simple laboratory features to
- distinguish the early stage of severe acute respiratory syndrome from dengue fever. Clin Infect Dis
- 567 *39*, 1818-1823.
- Wu, Z., and McGoogan, J.M. (2020). Characteristics of and Important Lessons From the Coronavirus
- Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the
- 570 Chinese Center for Disease Control and Prevention. JAMA.
- 571 Yan, B., Chu, H., Yang, D., Sze, K.-H., Lai, P.-M., Yuan, S., Shuai, H., Wang, Y., Kao, R.Y.-T., Chan,
- J.F.-W., et al. (2019). Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells:
- 573 Implications for Lipid Metabolism Remodeling upon Coronavirus Replication. Viruses 11, 73.
- Zheng, Y., Zhang, Y., Chi, H., Chen, S., Peng, M., Luo, L., Chen, L., Li, J., Shen, B., and Wang, D.
- 575 (2020). The hemocyte counts as a potential biomarker for predicting disease progression in
- 576 COVID-19: a retrospective study. CCLM clinical chemistry and laboratory medicine 58.
- Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C., and
- 578 Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-
- 579 level datasets. Nat Commun 10, 1523.
- Zou, Z., Yang, Y., Chen, J., Xin, S., Zhang, W., Zhou, X., Mao, Y., Hu, L., Liu, D., Chang, B., et al. (2004).
- Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases. Clin Infect
- 582 Dis *38*, 483-489.

583

584 585

Table 1. Demographics and baseline characteristics of COVID-19 patients.

Variables	Healthy Control (N=28)	non-COVID- 19 (N=25)	COVID-19			
			Total	non-Severe	Severe	
			(N=46)	(N=25)	(N=21)	
Sex - no. <sup>a</sup> (%)						
Male	21 (75.0)	17 (68.0)	31 (67.4)	18 (72.0)	13 (61.9)	
Female	7 (25.0)	8 (32.0)	15 (32.6)	7 (28.0)	8 (38.1)	
Age - yr. <sup>b</sup>						
Mean ± SD	44.4±8.3	49.2±14.0	47.7±13.9	42.2±12.8	54.3±12.4	
Median (IQR)	45.0	53.0	46.5	43.0	55.0	
	(38.0-51.0)	(37.0-61.0)	(35.8-59.0)	(33.0-50.0)	(47.0-63.0)	
Range	28.0-57.0	23.0-67.0	20.0-75.0	20.0-70.0	30.0-75.0	
BMI, kg/m²						
Mean ± SD °	24.4±2.7	23.5±2.7	24.9±3.0	24.5±3.3	26.0±2.4	
Median (IQR) <sup>d</sup>	24.2	24.7	24.8	24.9	25.8	
	(22.5-26.5)	(20.9-25.8)	(22.7-27.0)	(21.7-26.8)	(24.4-28.0)	
Range	19.9-32.9	19.1-27.4	19.0-31.3	18.9-30.4	22.2-31.3	
Smoke - no. (%)			5 (10.9)	2 (8.0)	1 (4.8)	
Alcohol - no. (%)			1 (2.2)	1 (4.0)	0 (0.0)	
Time from onset to ad	lmission, days					
Mean ± SD			3.0±4.2	1.6±2.1	4.6±5.4	
Median (IQR)			1.5	1.0	2.0	
			(0.0-4.0)	(0.0-2.0)	(0.5-6.0)	
Range			0.0-20.0	0.0-10.0	0.0-20.0	
Time from admission	to severe, days					
Mean ± SD					4.0±2.1	
Median (IQR)					4.0 (2.5-5.5	
Range					0.0-7.0	
Symptoms - no. (%)						
Fever		9 (36.0)	34 (73.9)	16 (64.0)	18 (85.7)	
Cough		11 (44.0)	26 (56.5)	13 (52.0)	13 (61.9)	
Headache		2 (8.0)	7 (15.2)	4 (16.0)	3 (14.3)	
Fatigue		2 (8.0)	8 (17.4)	5 (20.0)	3 (14.3)	
Pharyngalgia		0 (0.0)	3 (6.5)	1 (4.0)	2 (9.5)	
Expectoration		3 (12.0)	12 (26.1)	4 (16.0)	8 (38.1)	
Diarrhea		0 (0.0)	3 (6.5)	1 (4.0)	2 (9.5)	
Chest tightness		2 (8.0)	1 (2.2)	1 (4.0)	0 (0.0)	
Chest CT <sup>e</sup> - no. (%)						
Involvement of chest ra	diographs	1 (4.0)	45 (97.8)	24 (96.0)	21 (100)	
Comorbidity- no. (%)						
Hypertension		10 (40.0)	6 (13.0)	1 (4.0)	5 (23.8)	

Respiratory system	2 (8.0)	4 (8.7)	3 (12.0)	1 (4.8)
Endocrine system	0 (0.0)	3 (6.5)	0 (0.0)	3 (14.3)
Chronic kidney disease	0 (0.0)	1 (2.2)	0 (0.0)	1 (4.8)
Digestive system	2 (8.0)	6 (13.0)	3 (12.0)	3 (14.3)
Oxygenation Index - mmHg				
Mean ± SD			478.4±147.5	347.4±124.1
Median (IQR)			447.6	341.4
			(390.5-506.0)	(266.5-381.9)
Range			289.7-890.5	133.3-728.6
Treatment - no. (%)				
Oxygen inhalation	3 (12.0)	30 (65.2)	10 (40.0)	20 (95.2)
Antibiotics	2 (2 2)	45 (00.0)	0 (22 0)	7 (22.2)
7 11 11 10 10 11 00	0 (0.0)	15 (32.6)	8 (32.0)	7 (33.3)
Antiviral drug	0 (0.0) 25 (100)	15 (32.6) 46 (100.0)	8 (32.0) 25 (100.0)	7 (33.3) 21 (100.0)
	, ,	` ,	` ,	` ,
Antiviral drug	25 (100)	46 (100.0)	25 (100.0)	21 (100.0)

588 a no. (%): number.

589 b yr.: year.

590 ° SD: Standard Deviation.

591 d IQR: Interquartile range

692 ° CT: Computed tomography

593

629

```
Figure 1. Summary of COVID-19 patients and machine learning design.
594
      (A) Summary of COVID-19 patients, including non-severe (n=25) and severe
595
      (n=21) patients with more details in Table S1. Patients labeled in red (Y-axis)
596
      indicate chronic infection of viruses including HBV. (B) Study design for
597
      machine learning-based classifier development for severe COVID-19 patients.
598
      We first procured samples in a training cohort for proteomic and metabolomic
599
      analysis. The classifier was then validated in an independent cohort.
600
      Figure 2. Separation of severe and non-severe COVID-19 patients by
601
      machine learning of proteomic and metabolomic features. (A) Top 22
602
      proteins and 7 metabolites prioritized by random forest analysis ranked by the
603
      mean decrease in accuracy. (B) Network of prioritized proteins appeared in
604
      the classifier. (C) ROC of the random forest model in the training cohort. (D)
605
      Principal Components Analysis (PCA) plot of COVID-19 patients from the
606
      training cohort. (E) Performance of the model in the validation cohort of ten
607
      COVID-19 patients. Patients labeled in red received serum test before they
608
609
      were diagnosed as severe.
      Figure 3. Dysregulated proteins in COVID-19 sera. (A) Heatmap of 50
610
      selected proteins whose regulation concentrated on three enriched pathways.
611
      (B) The expression level change (z-scored original value) of six selected
612
      proteins of interest with significance indicated by the asterisks (unpaired two
613
      sided Welch's t test. p value: ***, <0.001; **, <0.01; *, <0.05)
614
      Figure 4. Dysregulated metabolites in COVID-19 sera. (A) Heatmap of 82
615
      regulated metabolites belonging to six major classes: fatty acids, steroids,
616
      glycerophospholipid, sphingolipid, choline and serotonins. (B) The expression
617
      level change (z-scored log2 original value) of six regulated metabolites from
618
      each metabolite class with significance indicated by the asterisks as
619
      described in Figure 3.
620
      Figure 5. Key proteins and metabolites characterized in severe COVID-
621
622
      19 patients in a working model. SARS-CoV-2 may target alveolar
      macrophages via ACE2 receptor with increasing level of cytokines including
623
      IL-6 and TNF-α, which subsequently induce the elevation of various APPs
624
      such as SAP, CRP, SAA1, SAA2 and C6 which are significantly upregulated
625
      in the severe group. Proteins involved in macrophage, lipid metabolism and
626
      platelet degranulation were indicated with their corresponding expression
627
      levels in four patient groups.
628
```

# **MATERIALS AND METHODS**

# Patients and samples

630

631

Our team procured serum samples from 46 patients who visited Taizhou 632 Public Health Medical Center during January 23 and February 4, 2020. They 633 were diagnosed as COVID-19 according to the Chinese Government 634 Diagnosis and Treatment Guideline (Trial 5th version)(Medicine, 2020). For 635 diagnosing COVID-19, nucleic acid from sputum or throat swab was extracted 636 using nucleic acid extractor (Shanghai Zhijiang, China, EX3600) and virus 637 nucleic acid extraction reagent (Shanghai Zhijiang, China, NO. P20200201) 638 was used to extract nucleic acid. Fluorescence quantitative PCR (ABI7500) 639 and SARS-CoV-2 nucleic acid detection kit (triple fluorescence PCR, 640 Shanghai Zhijiang, China, NO. P20200203) were used for nucleic acid 641 detection. This kit uses one step RT-PCR combined with Tagman technology 642 to detect RdRp, E and N genes. Positive was concluded if RdRp gene was 643 644 positive (Ct < 43), and one of E or N was positive (Ct <43). Patients were also 645 diagnosed as positive if two sequential tests of RdRp were positive while E and N were negative. According to the abovementioned guideline, COVID-19 646 patients are classified into four subgroups: 1) Mild: mild symptoms without 647 pneumonia; 2) Typical: fever or respiratory tract symptoms with pneumonia; 3) 648 Severe: fulfill any of the three criteria: respiratory distress, respiratory rate ≥ 649 30 times/min; means oxygen saturation ≤ 93% in resting state; arterial blood 650 651 oxygen partial pressure/oxygen concentration ≤ 300 mmHg (1 mmHg = 0.133 kPa); 4) Critical: fulfill any of the three criteria: respiratory failure and require 652 mechanical ventilation; shock incidence; admission to ICU with other organ 653 failure. In this study, we included both severe and no-severe patients, with the 654 latter composed of mild and typical COVID-19 patients. Last follow-up of 655 these patients was March 10, 2020. We also procured 25 non-COVID-19 656 patients with similar clinical characteristics including fever and/or cough as 657 COVID-19 patients however negative in the nucleic acid test. Based on the 658 Chinese Government Diagnosis and Treatment Guideline (Trial 5th version) 659 (Medicine, 2020), patients are defined as suspected COVID-19 cases when 660 they meet the following three clinical criteria: 1) fever or respiratory symptoms, 661 2) imaging manifestation of pneumonia, and 3) optional reduction of white 662 blood cell or lymphocyte count at early stage. The patients only need to meet 663 at least two of the above three criteria if they have been exposed to COVID-664 19 individuals. We also collected serum samples from 28 healthy individuals 665 as control. All the serum samples were collected as venous whole blood in the 666 early morning before diet using serum separation tubes (Zhejiang GongDong 667 Medical Technology Co., Ltd, China). The blood samples were centrifuged at 668 3,500 rpm for 10 min for serum collection. The serum samples were frozen at 669 670 -80°C. The samples from this study is from a clinical trial that our team initiated and registered in the Chinese Clinical Trial Registry with a ID of 671 ChiCTR2000031365. This study has been approved by the 672

Ethical/Institutional Review Board of Taizhou Public Health Medical Center and Westlake University. Contents from patients were waived by the boards.

674675676

673

## **Proteomic analysis**

Serum samples were inactivated and sterilized at 56°C for 30 min, and 677 processed as previously with some modifications. Five µL serum from each 678 specimen was lysed in 50 µL lysis buffer (8 M urea in 100 mM 679 triethylammonium bicarbonate, TEAB) at 32°C for 30 min. The lysates were 680 reductive with 10 mM tris (2-carboxyethyl) phosphine (TCEP) for 30 min at 681 32°C, then alkylated for 45 min with 40 mM iodoacetamide (IAA) in darkness 682 at room temperature (25°C). The protein extracts were diluted with 200 µL 100 683 mM TEAB, and digested with double-step trypsinization (Hualishi Tech. Ltd., 684 Beijing, China), each step with an enzyme-to-substrate ratio of 1:20, at 32°C 685 for 60 min. The reaction was stopped by adding 30 µL 10% trifluoroacetic acid 686 (TFA) in volume. Digested peptides were cleaned-up with SOLAµ (Thermo 687 Fisher Scientific™. San Jose, USA) following the manufacturer's instructions. 688 and lableled with TMTpro 16plex label reagents (Thermo Fisher Scientific™, 689 San Jose, USA) as described previously. The TMT samples were fractionated 690 using a nanoflow DIONEX UltiMate 3000 RSLCnano System (Thermo Fisher 691 Scientific™, San Jose, USA) with an XBridge Peptide BEH C18 column (300 692 Å, 5 µm × 4.6 mm × 250 mm) (Waters, Milford, MA, USA)(Gao et al., 2020). 693 The samples were separated using a gradient from 5% to 35% acetonitrile 694 695 (ACN) in 10 mM ammonia (pH=10.0) at a flow rate of 1 mL/min. Peptides were separated into 120 fractions, which were consolidated into 40 fractions. 696 The fractions were subsequently dried and re-dissolved in 2% ACN/0.1% 697 formic acid (FA). The re-dissolved peptides were analyzed by LC-MS/MS with 698 the same LC system coupled to a Q Exactive HF-X hybrid Quadrupole-699 Orbitrap (Thermo Fisher Scientific™, San Jose, USA) in data dependent 700 acquisition (DDA) mode. For each acquisition, peptides were loaded onto a 701 precolumn (3 µm, 100 Å, 20 mm\*75 µm i.d.) at a flowrate of 6 µL/min for 4 min 702 and then injected using a 35 min LC gradient (from 5% to 28% buffer B) at a 703 flowrate of 300 nL/min (analytical column, 1.9 μm, 120 Å, 150 mm\*75 μm i.d.). 704 Buffer A was 2%ACN, 98% H<sub>2</sub>O containing 0.1% FA, and buffer B was 98% 705 ACN, 2% H<sub>2</sub>O containing 0.1% FA. All reagents were MS grade. The m/z 706 range of MS1 was 350-1,800 with the resolution at 60,000 (at 200 m/z), AGC 707 target of 3e6, and maximum ion injection time (max IT) of 50 ms. Top 15 708 precursors were selected for MS/MS experiment, with a resolution at 45,000 709 (at 200 m/z), AGC target of 2e5, and max IT of 120 ms. The isolation window 710 of selected precursor was 0.7 m/z. The resultant mass spectrometric data 711 were analyzed using Proteome Discoverer (Version 2.4.1.15, Thermo Fisher 712 713 Scientific) using a protein database composed of the *Homo sapiens* fasta 714 database downloaded from UniprotKB on 07 Jan 2020 and the SARS-CoV-2 virus fasta downloaded from NCBI (version NC 045512.2). Enzyme was set 715 to trypsin with two missed cleavage tolerance. Static modifications were set to 716

carbamidomethylation (+57.021464) of cysteine, TMTpro (+304.207145) of lysine residues and peptides' N termini, and variable modifications were set to oxidation (+15.994915) of methionine and acetylation (+42.010565) of peptides' N-termini. Precursor ion mass tolerance was set to 20 ppm, and product ion mass tolerance was set to 0.06 Da. The peptide-spectrum-match allowed 1% target false discovery rate (FDR) (strict) and 5% target FDR (relaxed). Normalization was performed against the total peptide amount. The other parameters followed the default setup.

# **Quality control of proteomic data**

The quality of proteomic data was ensured at multiple levels. First, a mouse liver digest was used for instrument performance evaluation. We also run water samples (buffer A) as blanks every 4 injections to avoid carry-over. Serum samples of four patient groups from both training and validation cohorts were randomly distributed in eight different batches. Six samples were injected in technical replicates.

#### Metabolomic analysis

Ethanol was added to the serum samples and shaken vigorously to inactivate any potential viruses, then dried in a biosafety hood. The dried samples were further treated for metabolomics analysis. The metabolomic analysis was performed as described previously (Lee et al., 2019). Briefly, deactivated serum samples, 100 µL each, were extracted by adding 300 µL extraction solution. The mixtures were shaken vigorously for 2 min. Proteins were denatured and precipitated by centrifugation. The supernatants contained metabolites of diverse chemical natures. To ensure the quantity and reliability of metabolite detection, four platforms were performed with nontarget metabolomics. Each supernatant was divided into four fractions: two for analysis using two separate reverse-phase /ultra-performance liquid chromatography (RP/UPLC)-MS/MS methods with positive ion-mode electrospray ionization (ESI), one for analysis using RP/ UPLC-MS/MS with negative-ion mode ESI, and one for analysis using hydrophilic interaction liquid chromatography (HILIC)/UPLC-MS/MS with negative-ion mode ESI. Each fraction was dried under nitrogen gas to remove the organic solvent and later re-dissolved in four different reconstitution solvents compatible with each of the four UPLC-MS/MS methods.

All UPLC-MS/MS methods used ACQUITY 2D UPLC system (Waters, Milford, MA, USA) and Q Exactive HF hybrid Quadrupole-Orbitrap (Thermo Fisher Scientific<sup>TM</sup>, San Jose, USA) with HESI-II heated ESI source and Orbitrap mass analyzer. The mass spectrometer was operated at 35,000 mass resolution (at 200 m/z). In the first UPLC-MS/MS method, the QE was operated under positive electron spray ionization (ESI) coupled with a C18 column (UPLC BEH C18, 2.1 × 100 mm, 1.7  $\mu$ m; Waters) was used in UPLC. The mobile solutions used in the gradient elution were water and methanol

containing 0.05% perfluoropentanoic acid (PFPA) and 0.1% FA. In the second method, the QE was still operated under ESI positive mode, and the UPLC used the same C18 column as in method one, but the mobile phase solutions were optimized for more hydrophobic compounds and contained methanol, acetonitrile, water, 0.05% PFPA, and 0.01% FA. The third method had the QE operated under negative ESI mode, and the UPLC method used a C18 column eluted with mobile solutions containing methanol and water in 6.5 mM ammonium bicarbonate at pH 8. The UPLC column used in the fourth method was HILIC column (UPLC BEH Amide, 2.1 × 150 mm, 1.7  $\mu$ m; Waters), and the mobile solutions were consisted of water and acetonitrile with 10 mM ammonium formate at pH 10.8; the QE was operated under negative ESI mode. The QE mass spectrometer analysis was alternated between MS and data-dependent MS2 scans using dynamic exclusion. The scan range was 70-1,000 m/z.

After raw data pre-processing, peak finding/alignment, and peak annotation using in-house software, metabolites were identified by searching an in-house library containing more than 3,300 standards with library data entries generated from running purified compound standards through the experimental platforms. Identification of metabolites must meet three strict criteria: narrow window retention index (RI), accurate mass with variation less than 10 ppm and MS/MS spectra with high forward and reverse scores based on comparisons of the ions present in the experimental spectrum to the ions present in the library spectrum entries. Almost all isomers can be distinguished by these three criteria. All identified metabolites meet the level 1 requirements by the Chemical Analysis Working Group (CAWG) of the Metabolomics Standards Initiative (MSI) expect some asterisk labeled lipids which MS/MS spectral were *in silico* matched.

#### Quality control of metabolomics analysis

Several types of quality control samples were included in the experiment: a pooled sample generated by taking a small volume of each experimental sample to serve as a technical replicate that was run multiple times throughout the experiment, extracted water samples served as blanks, and extracted commercial plasma samples for monitoring instrument variation. A mixture of internal standards was also spiked into every sample to aid chromatographic peak alignment and instrument stability monitoring. Instrument variability was determined by calculating the median relative SD (RSD) of all internal standards in each sample. The experimental process variability was determined by calculating the median RSD for all endogenous metabolites present in the pooled quality control samples.

#### Statistical analysis

Metabolites and therapeutic compounds with over 80% missing ratios in a particular patient group were removed for the metabolomics dataset

SHEN, ET AL 21

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819 820

821

822

823824

825

826827

828

829

830

831

832 833

834

835 836 containing endogenoeous metabolites while full proteomics features were used for the subsequent statistical analysis. Missing values were imputated with the minimal value for each feature. Log2 fold-change (log2 FC) was calculated on the mean of the same patient group for each pair of comparing groups. Two-sided unpaired Welch's t test was performed for each pair of comparing groups and adjusted p values were calculated using Benjamini & Hochberg correction. The statistical significantly changed proteins or metabolites were selected using the criteria of adjust p value less than 0.05 indicated and absolute log2 FC larger than 0.25. From the training cohort, the important features were selected with mean decrease accuracy larger than 3 using random forest containing a thousand trees using R package randomForest (version 4.6.14) random forest analysis with 10-fold cross validation as binary classification of paired severe and non-severe group using combined differentially regulated proteins and metabolites features. The random forest analysis was further performed for a hundred times on the matrix with only the selected important features using normalized additive predicting probability as the final predicting probability and the larger probability as the predictive label. Those selected important features were used for the random forest analysis on the independent validation cohort.

Pathway analysis

Four network pathway analysis tools were used for pathway analysis using 93 differentially expressed proteins (DEPs). The top Gene Ontology (GO) processes were enriched by Metascape web-based platform (Zhou et al., 2019). The GO terms is enriched using the Cytoscape plug-in ClueGO (Bindea et al., 2009). Ingenuine pathway analysis (Kramer et al., 2014) of the regulated proteins identifies most significantly relevant pathways with p value of determined based on right-tailed Fisher's Exact Test with the overall activation or inhibition states of enriched pathways were predicted by z-score. Functional co-expression network analysis by GeNet(Li et al., 2018a) to represent statistical co-expressed protein modules.

869

870

871


Molecular profiling of COVID-19 sera Figure S1. Quality control of proteomic and metabolomic data. (A) 837 Coefficient of variation (CV) of the proteomic data is calculated by the proteins 838 quantified in six quality control (QC) samples using the pooled samples from 839 all samples in training cohort. CV of the metabolomic data is calculated by 840 twelve QC samples using a set of isotopic internal spiked-in standards. (B) 841 UMAP of sera samples using 791 measured proteins. (C) UMAP of sera 842 samples using 847 metabolites. 843 Figure S2. Differentially expressed proteins in different patient groups in 844 the training cohort. Volcano plots compare four pairs of patient groups as 845 indicated in the plot. Proteins with log2 (fold-change) beyond 0.25 or below -846 0.25 with adjusted p value lower than 0.05 were considered as significantly 847 differential expression. Number of significantly down- (blue) and up- (red) 848 regulated proteins were shown on the top. 849 Figure S3. Differentially expressed metabolites in different patient 850 groups in the training cohort. The volcano plots follow that for Figure S3 851 852 except metabolomic data were used as the input. 853 Figure S4. Proteins and metabolites regulated in COVID-19 patients but not in non-COVID-19 patients. Venn diagrams showing the overlaps 854 between significantly regulated proteins (A) and metabolites (B) as identified 855 in volcano plots. Proteins and metabolites labeled in red are the shortlisted 856 molecules which differentially expressed in the COVID-19 patients but not in 857 the non-COVID-19 patients. 858 859 Figure S5. Identification of specific clusters of proteins and metabolites in COVID-19 patients. 791 proteins (A) and 941 metabolites (B) were 860 clustered using mFuzz into 16 significant discrete clusters, respectively, to 861 illustrate the relative expression changes of the proteomics and metabolomics 862 data. The groups in proteomics data: 1: Healthy; 2: non-Severe COVID-19; 3: 863 Severe COVID-19. The groups in metabolomics data: 1: Healthy; 2: non-864 COVID-19; 3: non-Severe COVID-19; 4: Severe COVID-19. 865 Figure S6. Pathway analysis of 93 differential expressed proteins in 866 COVID-19 patients. (A) The Gene Ontology (GO) processes enriched by 867 Metascape. (B) The GO terms enriched using the Cytoscape plug-in ClueGO. 868


SHEN, ET AL 23

(C) Ingenuine pathway analysis of most significantly relevant pathways with

GeNet identifies several communities.

the predicted activation or inhibition state. (D) Functional network analysis by














Figure 5









Severe / Healthy

Severe / Healthy

Figure S5 Expression changes Cluster 1 Expression changes Cluster 2 Expression changes Cluster 3 Expression changes Cluster 4 -1.0 0.5-1.0 0.5-1.0 0.51 2 3 1 2 1 2 Expression changes Cluster 5 Expression changes Cluster 6 Expression changes Cluster 7 Expression changes Cluster 8 -1.0 0.5-1.0 0.5-1.0 0.5-1.0 0.51 2 2 В Cluster 1 Cluster 2 Cluster 3 Cluster 4 Expression changes Expression changes Expression changes Expression changes -1.0 1.0 -1.5 0.5-1.0 0.52 3 2 3 2 3 2 Cluster 5 Cluster 6 Cluster 7 Cluster 8 Expression changes Expression changes Expression changes Expression changes -1.0 1.0 -1.0 1.0 -1.0 1.0 -1.5 0.53 3 2 3 2 2 Expression changes Cluster 9 Cluster 10 Cluster 11 Cluster 12 Expression changes Expression changes Expression changes -1.0 1.0 0.5 0.5 -1.5 0.0-1.5 -1.5 3 2 3 2 3 2 2 3 Cluster 13 Cluster 14 Cluster 15 Cluster 16 Expression changes Expression changes Expression changes Expression changes -1.0 1.0 -1.0 1.0 -1.0 0.5 -1.0053 3 2 3 3 2 2

